Company profile: NapaJen
1.1 - Company Overview
Company description
- Provider of oligonucleotide therapeutics and delivery technologies, offering NJA-730 for preventing acute immune diseases tied to bone marrow transplants; Napa9-SPG, a TLR9 agonist in preclinical immuno-oncology and vaccine adjuvant use; and a proprietary platform delivering nucleic acid drugs to immune cells. Provides partnerships for oligonucleotide development and NJA-730 licensing.
Products and services
- NJA-730: Novel oligonucleotide drug engineered to prevent acute immune diseases associated with bone marrow transplants, serving as NapaJen’s lead drug candidate
- Oligonucleotide Delivery Platform: Proprietary delivery technology that transports nucleic acid-based drugs to target immune cells, addressing critical delivery challenges for immune-targeted therapeutics
- Napa9-SPG: Preclinical-stage TLR9 agonist advancing immuno-oncology applications and serving as a vaccine adjuvant, designed to robustly activate toll-like receptor 9 pathways
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NapaJen
Cell IDx
HQ: United States
Website
- Description: Provider of multiplexed cellular immunodiagnostics solutions, developing highly sensitive and specific reagents for research and clinical immunohistochemistry, and offering UltraPlex technology for multiplex chromogenic and fluorescent tissue staining suitable for high-throughput biomarker tissue profiling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cell IDx company profile →
Avidia
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies focused on discovering and developing therapeutic proteins. Offers Avimer therapeutic proteins addressing multiple therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Founded in 2003 and headquartered in Mountain View, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avidia company profile →
Galapagos
HQ: Belgium
Website
- Description: Provider of small molecule medicines and investigational therapies in immunology and oncology. Develops CAR-T cell therapies via a decentralized manufacturing network and advances GLPG5101 (Phase 1/2 for relapsed/refractory non-Hodgkin lymphoma). Conducts clinical trials to evaluate treatments and seek regulatory approval; Jyseleca (filgotinib) transferred to Alfasigma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galapagos company profile →
Veloxis Pharmaceuticals
HQ: Denmark
Website
- Description: Provider of specialty pharmaceuticals for kidney transplant patients, focused on the development and commercialization of ENVARSUS XR, a once-daily extended-release tacrolimus tablet to prevent organ rejection and facilitate switching from immediate-release formulations, and VEL-101, an investigational immunosuppressant blocking CD28-mediated T cell activation while preserving CTLA-4 functions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Veloxis Pharmaceuticals company profile →
Kezar Life Sciences
HQ: United States
Website
- Description: Provider of drug discovery and development focused on protein homeostasis, offering Zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for autoimmune diseases via immune modulation without direct immunosuppression, and KZR-261, a first-in-class Sec61 translocon inhibitor for advanced/metastatic solid tumors that blocks key secreted proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kezar Life Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NapaJen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NapaJen
2.2 - Growth funds investing in similar companies to NapaJen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NapaJen
4.2 - Public trading comparable groups for NapaJen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →